Global Breast Cancer Diagnostics Market to Surpass USD 2 Billion by 2022

The global breast cancer diagnostics market is anticipated to register a modest CAGR of 4.7% between 2017 and 2022 to surpass USD 2 billion in revenues by the end of the forecast period.

The market growth is expected to be driven by a surge in the number of breast cancer cases, thereby increasing the need for efficient and initial detection, as well as by the introduction of high-end technological assistance to provide conclusive test results. These are the latest findings of Fact.MR, (Dublin, Ireland), a market research firm.

Based on test type, BRCA is expected to dominate the global breast cancer diagnostics market with the highest revenue share and achieve sales of USD 500 million by 2022-end. However, the CA test type segment is projected to register the highest CAGR in the breast cancer diagnostics market through 2022, followed by the ER and PR test type segments. HER 2 test is expected to be the second-largest test type segment in the global breast cancer diagnostics market, whereas revenues of the EGFR mutation test type segment are likely to remain low. Hospital-associated laboratories are expected to remain the largest end-user of breast cancer diagnostics globally and record the highest revenues by 2022-end, followed by independent diagnostic laboratories.

Geographically, North America has the highest revenue share in the global breast cancer diagnostics market and will retain its leading position with projected revenues of more than USD 800 million by 2022-end. On the other hand, Europe will have the second-largest share in revenues of the global breast cancer diagnostics market, while the regional markets in Japan and the Middle East & Africa (MEA) are projected to witness a slow growth during the forecast period.

Related Links:
Fact.MR